Ontology highlight
ABSTRACT:
SUBMITTER: Bera TK
PROVIDER: S-EPMC4182334 | biostudies-literature | 2014 Oct
REPOSITORIES: biostudies-literature
Bera Tapan K TK Onda Masanori M Kreitman Robert J RJ Pastan Ira I
Leukemia research 20140705 10
Moxetumomab pasudotox (HA22) is a recombinant immunotoxin, now in clinical trials, that combines an anti-CD22-Fv with a 38-kDa fragment of Pseudomonas exotoxin A. To produce a less immunogenic molecule without reducing the half-life in circulation, we constructed LMB11 combining an anti-CD22 Fab with a less immunogenic version of PE38. We found that LMB11 retains full activity toward CD22-expressing cells. In mice, the half-life of LMB11 is 29 min and the antitumor activity of LMB11 is better th ...[more]